lovastatin has been researched along with Bright Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (25.00) | 18.7374 |
| 1990's | 8 (66.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tareeva, IE | 1 |
| Davis, P; Exner, M; Kerjaschki, D; Neale, TJ; Ojha, PP; Poczewski, H; Rüger, B; Witztum, JL | 1 |
| Neugarten, J; Rubin, R; Sablay, L; Silbiger, S | 1 |
| Guijarro, C; Keane, WF | 1 |
| Kaysen, GA; Neverov, NI; Tareyeva, IE | 1 |
| Ideura, T; Inui, K; Iwasaki, S; Nabeshima, K; Sugenoya, Y; Uda, S; Yoshimura, A | 1 |
| Kolina, IB; Neverov, NI; Shilov, EM; Shvetsov, MIu; Stavrovskaia, EV; Zakharova, EV | 1 |
| Chan, PC; Cheng, IK; Robinson, JD; Tsang, MT; Yeung, HW; Yeung, WC | 1 |
| Harris, KP; Klahr, S; Purkerson, ML; Yates, J | 1 |
| Garvis, WJ; Kasiske, BL; Keane, WF; O'Donnell, MP | 1 |
| Cleary, MP; Kasiske, BL; Keane, WF; O'Donnell, MP | 1 |
| Kasiske, BL; Keane, WF; O'Donnell, MP | 1 |
1 review(s) available for lovastatin and Bright Disease
| Article | Year |
|---|---|
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
Topics: Animals; Anticholesteremic Agents; Cell Division; Collagen; Colony-Stimulating Factors; Extracellular Matrix Proteins; Gene Expression; Glomerular Mesangium; Glomerulonephritis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Kidney; Kidney Failure, Chronic; Lovastatin; Mevalonic Acid | 1996 |
3 trial(s) available for lovastatin and Bright Disease
| Article | Year |
|---|---|
[New approaches to the treatment of nephritis].
Topics: Animals; Cells, Cultured; Chronic Disease; Cyclophosphamide; Glomerulonephritis; Humans; Lovastatin; Lupus Nephritis; Mice; Nephritis; Nephrosclerosis; Nephrotic Syndrome; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Time Factors | 1995 |
Effect of lipid-lowering therapy on the progression of renal disease in nondiabetic nephrotic patients.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Chronic Disease; Creatinine; Diet, Fat-Restricted; Disease Progression; Female; Glomerulonephritis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lipoproteins; Lovastatin; Male; Middle Aged; Proteinuria | 1997 |
Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria.
Topics: Adult; Aged; Drug Tolerance; Female; Glomerulonephritis; Humans; Hyperlipidemias; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Proteinuria; Rhabdomyolysis | 1992 |
8 other study(ies) available for lovastatin and Bright Disease
| Article | Year |
|---|---|
Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen.
Topics: Aldehydes; Animals; Anticholesteremic Agents; Antigen-Antibody Complex; Basement Membrane; Cholesterol; Collagen; Disease Models, Animal; Epithelial Cells; Glomerulonephritis; Kidney Glomerulus; Lipid Peroxidation; Lovastatin; Lysine; Male; Malondialdehyde; Probucol; Proteinuria; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Simvastatin | 1994 |
Combined antihypertensive and lipid-lowering therapy in experimental glomerulonephritis.
Topics: Animals; Antihypertensive Agents; Cholesterol; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Hypertension; Lovastatin; Male; Rats; Rats, Sprague-Dawley | 1994 |
HMG-CoA reductase inhibitor suppression of glomerular cell proliferation in rats with anti-Thy-1.1 nephritis.
Topics: Actins; Animals; Cell Division; Cells, Cultured; Glomerular Mesangium; Glomerulonephritis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Isoantibodies; Lovastatin; Macrophages; Male; Muscle, Smooth; Rats; Rats, Wistar; Simvastatin | 1997 |
[Effects of pathogenetic therapy on blood cholesterol in patients with glomerulonephritis].
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anticholesteremic Agents; Antihypertensive Agents; Azathioprine; Captopril; Cholesterol; Creatinine; Cyclophosphamide; Data Interpretation, Statistical; Enalapril; Female; Glomerulonephritis; Humans; Immunosuppressive Agents; Lovastatin; Male; Nephrotic Syndrome; Prednisolone; Retrospective Studies; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome.
Topics: Animals; Blood Urea Nitrogen; Cholesterol; Female; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hypercholesterolemia; Kidney Glomerulus; Lovastatin; Nephrotic Syndrome; Rats; Rats, Inbred Strains; Uremia | 1990 |
Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure.
Topics: Animals; Cholesterol; Clofibrate; Clofibric Acid; Disease Models, Animal; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Kidney; Kidney Failure, Chronic; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Nephrons; Rats; Rats, Inbred Strains; Triglycerides | 1988 |
Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats.
Topics: Albuminuria; Animals; Cholesterol; Clofibrate; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Lovastatin; Male; Obesity; Rats; Rats, Zucker; Triglycerides | 1988 |
The role of lipids in progressive glomerular disease.
Topics: Animals; Clofibric Acid; Glomerulonephritis; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipidemias; Hypertension, Renal; Lipid Metabolism; Lovastatin; Rats; Rats, Zucker | 1987 |